See more : Beijer Electronics Group AB (publ) (BELE.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Ikena Oncology, Inc. (IKNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ikena Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- DCD Media Plc (DCD.L) Income Statement Analysis – Financial Results
- Sunlands Technology Group (STG) Income Statement Analysis – Financial Results
- Sichuan Em Technology Co., Ltd. (601208.SS) Income Statement Analysis – Financial Results
- Coliseum Acquisition Corp. (MITA) Income Statement Analysis – Financial Results
- I Jang Industrial Co.,Ltd. (8342.TWO) Income Statement Analysis – Financial Results
Ikena Oncology, Inc. (IKNA)
About Ikena Oncology, Inc.
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 9.16M | 15.62M | 30.99M | 9.19M | 13.75M | 990.00K |
| Cost of Revenue | 1.02M | 2.03M | 47.11M | 44.85M | 24.94M | 38.99M |
| Gross Profit | 8.14M | 13.58M | -16.12M | -35.65M | -11.19M | -38.00M |
| Gross Profit Ratio | 88.86% | 86.98% | -52.03% | -387.79% | -81.33% | -3,837.98% |
| Research & Development | 59.65M | 64.32M | 47.11M | 44.85M | 24.94M | 38.56M |
| General & Administrative | 24.93M | 22.20M | 18.02M | 8.87M | 7.31M | 2.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.93M | 22.20M | 18.02M | 8.87M | 7.31M | 2.90M |
| Other Expenses | 0.00 | -10.00K | 23.00K | 263.00K | 1.68M | 0.00 |
| Operating Expenses | 84.58M | 86.52M | 65.12M | 53.71M | 32.25M | 41.46M |
| Cost & Expenses | 84.58M | 86.52M | 65.12M | 53.71M | 32.25M | 41.88M |
| Interest Income | 7.11M | 2.15M | 23.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 2.15M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.02M | 2.03M | 1.72M | 1.26M | 122.00K | 422.00K |
| EBITDA | -74.40M | -70.15M | -33.59M | -44.22M | -18.25M | -40.44M |
| EBITDA Ratio | -812.19% | -449.18% | -108.42% | -480.95% | -132.69% | -4,088.08% |
| Operating Income | -75.42M | -70.90M | -34.14M | -44.52M | -18.49M | -40.89M |
| Operating Income Ratio | -823.33% | -453.99% | -110.18% | -484.22% | -134.46% | -4,130.71% |
| Total Other Income/Expenses | 7.09M | 2.14M | 23.00K | 263.00K | 1.68M | 29.00K |
| Income Before Tax | -68.33M | -68.77M | -34.12M | -44.26M | -16.82M | -40.87M |
| Income Before Tax Ratio | -745.94% | -440.29% | -110.10% | -481.36% | -122.28% | -4,127.78% |
| Income Tax Expense | -162.00K | -2.14M | 307.44K | 93.70K | 71.14K | 0.00 |
| Net Income | -68.17M | -66.63M | -34.12M | -44.26M | -16.82M | -40.87M |
| Net Income Ratio | -744.17% | -426.60% | -110.10% | -481.36% | -122.28% | -4,127.78% |
| EPS | -1.63 | -1.84 | -0.95 | -1.23 | -0.47 | -1.14 |
| EPS Diluted | -1.63 | -1.84 | -0.95 | -1.23 | -0.47 | -1.14 |
| Weighted Avg Shares Out | 41.74M | 36.19M | 35.98M | 35.85M | 35.85M | 35.85M |
| Weighted Avg Shares Out (Dil) | 41.74M | 36.19M | 35.98M | 35.85M | 35.85M | 35.85M |
Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates
Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of -11.90% and 4.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Ikena Oncology (IKNA) This Earnings Season?
Ikena Oncology (IKNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Biotech Stocks Set to Outpace Q1 Earnings Estimates
Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.
Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that it will be presenting two trial-in-progress posters at the American Society of Clinical...
Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting
BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that it will participate in an oral presentation highlighting the company's novel TEAD inhibitor, IK-930,...
Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment
BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that the Company will present two virtual posters at the AACR-NCI-EORTC International Conference on...
Ikena Oncology to Present a Trial-in-Progress Update, Translational Data, and Indication Selection Methodology for Novel AHR Inhibition Program at the 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three abstracts highlighting the company's Aryl Hydrocarbon Receptor (AHR) antagonist program, with novel inhibitor...
Ikena Oncology to Participate in September 2021 Virtual Investor Conferences
BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today announced that management will participate in the virtual Morgan Stanley 19th Annual Global...
Ikena Oncology to Participate in Targeted Oncology Panel at the William Blair Biotech Focus Conference 2021
BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced that Dr. Mark Manfredi, CEO of...
Ikena Oncology Announces Pricing of Initial Public Offering
BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the pricing of its initial public offering of 7,812,500 shares of common...
Source: https://incomestatements.info
Category: Stock Reports